Eli Lilly and Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for Eli Lilly and.

Eli Lilly and Company (NYSE:LLY) issued its earnings results on Thursday, January, 28th. The company reported $2.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.35 by $0.40. The company earned $7.44 billion during the quarter, compared to analyst estimates of $7.27 billion. Eli Lilly and had a trailing twelve-month return on equity of 166.45% and a net margin of 24.01%. Eli Lilly and's revenue for the quarter was up 21.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.73 EPS.
View Eli Lilly and's earnings history.

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LLY stock has increased by 46.1% and is now trading at $204.52.
View which stocks have been most impacted by COVID-19.

Eli Lilly and announced a quarterly dividend on Monday, December 14th. Shareholders of record on Friday, February 12th will be paid a dividend of $0.85 per share on Wednesday, March 10th. This represents a $3.40 annualized dividend and a yield of 1.66%. The ex-dividend date is Thursday, February 11th. This is a boost from Eli Lilly and's previous quarterly dividend of $0.74.
View Eli Lilly and's dividend history.

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.68%. Eli Lilly and does not yet have a strock track record of dividend growth. The dividend payout ratio of Eli Lilly and is 56.29%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 42.61% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

Eli Lilly and issued an update on its FY21 earnings guidance on Friday, January, 29th. The company provided EPS guidance of $7.75-8.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19. The company issued revenue guidance of $26.5-28.0 billion, compared to the consensus revenue estimate of $27.60 billion.

15 equities research analysts have issued 1-year target prices for Eli Lilly and's shares. Their forecasts range from $144.00 to $235.00. On average, they anticipate Eli Lilly and's stock price to reach $192.60 in the next year. This suggests that the stock has a possible downside of 5.8%.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Endo International (ENDP) and Supernus Pharmaceuticals (SUPN).
View all of LLY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.15%), Primecap Management Co. CA (3.84%), FMR LLC (2.68%), Price T Rowe Associates Inc. MD (1.26%), Northern Trust Corp (1.13%) and Bank of New York Mellon Corp (0.97%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, David A Ricks, Donald A Zakrowski, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

LLY stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, BlackRock Inc., Nuveen Asset Management LLC, Primecap Management Co. CA, AJO LP, Winslow Capital Management LLC, and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Eli Lilly and company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill, and Stephen F Fry.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

LLY stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Avidity Partners Management LP, Brandywine Global Investment Management LLC, Lord Abbett & CO. LLC, Clearbridge Investments LLC, Morgan Stanley, Fisher Asset Management LLC, and PFM Health Sciences LP. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $204.52.

Eli Lilly and has a market capitalization of $196.02 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis.

Eli Lilly and employs 35,065 workers across the globe.

The official website for Eli Lilly and is www.lilly.com.

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]